Processa PharmaceuticalsPCSA
13F holders, Q1 2026 (March 31)10holders
2new positions
3sold out
$2.52avg. 13F price*
At the end of Q1 2026, 10 institutions reported holding Processa Pharmaceuticals Inc. (PCSA) in their 13F filings, unchanged from Q4 2025. 2 opened new positions and 3 sold out. The largest holders were Connective Capital Management, LLC ($179K), Stonepine Capital Management, LLC ($139K) and Geode Capital Management, LLC ($63K).
- Company
- Processa Pharmaceuticals Inc.
- CUSIP
- 74275C403
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $179K |
| Exits | 3 | $143K |
All 13F filers, Q4 2025 → Q1 2026: 123,012 shares bought and 60,480 shares sold, net +62,532 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Connective Capital Management, LLC | 0.15% | New | 70,736 | $179K |
| Stonepine Capital Management, LLC | 0.12% | Add +346.3% | 55,000 | $139K |
| Geode Capital Management, LLC | 0.00% | Add +62.5% | 24,908 | $63K |
| Vanguard Capital Management LLC | 0.00% | — | 12,729 | $32K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 10,857 | $27K |
| UBS Group AG | 0.00% | Reduce -80.0% | 2,531 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -34.0% | 918 | $2K |
| Citigroup Inc. | 0.00% | New | 14 | $35 |
| Jones Financial Companies LLLP | 0.00% | No change | 7 | $17 |
| Wells Fargo & Company | 0.00% | No change | 6 | $15 |
"% of holder's portfolio" is PCSA's weight in each manager's 13F, not the share of Processa Pharmaceuticals Inc. the manager owns.